RxDoctor Payments Data

Nisha Gandhi, MD

Advanced Heart Failure and Transplant Cardiology · Langhorne, PANPI 1700176989

Payments from drug & device makers

$3,713in general payments, 2019–2025

Across 169 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novartis$360
  • Impulse Dynamics (USA) Inc.$320
  • Amgen$239
  • Johnson & Johnson$238
  • AstraZeneca$222
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,699100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,713 in reported general payments places this provider in the 30th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$122,048
Medicare patients
242
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis13$292,662
VyndaqelTafamidis Meglumine13$259,546
EntrestoSacubitril/Valsartan133$191,706
JardianceEmpagliflozin110$117,613
FarxigaDapagliflozin Propanediol47$63,796
Bumetanide120$8,169
Metoprolol Succinate217$3,180
Tacrolimus15$1,883
Potassium Chloride51$1,477
Eplerenone19$1,470
Spironolactone147$1,363
Furosemide143$999
Carvedilol102$943
Hydralazine Hcl41$739
Torsemide13$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel$163$552,20826 claims
NovartisEntresto$360$191,706133 claims
Boehringer IngelheimJardiance$24$117,613110 claims
AstraZenecaFarxiga$222$63,79647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →